220 likes | 317 Views
Collateral Damage From HLA Mismatching. Gerhard Opelz. Rejection Treatment During 1 st Year Deceased Donor Kidney Transplants 1990-2012 . +84%. Rejection Treatment During 1 st Year. A+B Mismatches 0 DR MM. DR Mismatches 0 A+B MM. +97%. +57%.
E N D
CollateralDamageFrom HLA Mismatching Gerhard Opelz
Rejection Treatment During 1stYearDeceasedDonorKidneyTransplants 1990-2012 +84%
Rejection Treatment During 1st Year A+B Mismatches 0 DR MM DR Mismatches 0 A+B MM +97% +57%
Steroid Dose at Year 1 (mg/kg/d) A+B Mismatches 0 DR MM DR Mismatches 0 A+B MM
*) > 90-Percentile Transplantation 89: 567-572, 2010
Non-Hodgkin LymphomaDeceasedDonorKidneyTransplants HLA-A HLA-B HLA-DR Transplantation 89: 567-572, 2010
Non-Hodgkin Lymphoma – EBV StatusKidneyTransplants 1995-2012 Transplantation 88: 962-67, 2009
Pediatric Recipients Transplantation 90: 292-297, 2010
Osteoporosisat Year 5 +50% Transplantation 91: 65-69, 2011
Hip Fracture +170% Transplantation 91: 65-69, 2011
Death With a Functioning GraftDeceasedDonorKidneyTransplants n=177,584 2% per year 5%
Death With a Functioning Graft Am J Transplant 12: 3031-3038, 2012
Causeof Death Infection Cardiovascular Cancer Am J Transplant 12: 3031-3038, 2012
Death With a Functioning Graft Am J Transplant 12: 3031-3038, 2012